The Board has convened an Extraordinary General Meeting of Shareholders of BioPorto A/S on Tuesday, February 26, 2013 at 3.00 p.m. as requested by a group of shareholders, see announcement no. 3 dated January 25, 2013. On the agenda is the election of board members and possibly deputy members.
The group of shareholders has put forward an overall proposal for the number of members and candidates for nomination for the Board.
The number of members is proposed expanded from four to five members along with two deputy members.
Then, the following candidates are nominated, all of whom stand for election: Carsten Lønfeldt, Marianne Weile, Roar Bjørk Seeger, Laura von Kobyletzki og Thomas Magnussen. Torben A. Nielsen and Claus Crone Fuglsang are deputy member candidates.
Board members Niels Tækker Foged and Peter Nordkild have stated that they make their mandates available and retire from the Board at the extraordinary general meeting.
Board candidate resumes:
Carsten Lønfeldt has since 2007 been elected for the board of BioPorto (appointed chairman throughout the period).Until the end of 2006, Carsten Lønfeldt was Group Director in Coloplast A/S following a twenty-year career of management responsibilities in the company within a number of strategic key areas such as economy and finance, IT, HR, planning, corporate control and investor relations. After retiring from Coloplast, Carsten Lønfeldt has concentrated on his efforts at various board positions and is a member of the Advisory Board for NASDAQ OMX Copenhagen.
Carsten Lønfeldt is born in 1947 and holds a M.Sc. (Econ) from Copenhagen Business School (1972).
Directorships: Chairman of the bord fin BioPorto, Investeringforeningen Nykredit Invest, Investeringsforeningen Nykredit Invest Engros, Placeringsforeningen Nykredit Invest, Specialforeningen Nykredit Invest, Dandrit Biotech,A/S, LHK Stillads A/S, GoMinisite ApS, Pirutech ApS and Fonden Dansk Standard. Vice chairman for Professionel Forening Institutionel Investor. Member of the board of ATP Invest III F.M.B.A., EMDInvest F.M.B.A, Emerging Markets Long-term Economic InvestmentFund (L.E.I.F.) F.M.B.A., Global volution InvestF.M.B.A., Investeringsforeningen Investin, Investin ProF.M.B.A, Investin professionel forening, Nykredit AIDA IIF.M.B.A., Nykredit KOBRA F.M.B.A., Nykredit KOBRA IIF.M.B.A., Nykredit KOBRA III F.M.B.A., Nykredit Mira IIIF.M.B.A., Pro-Target Invest F.M.B.A., Polaris Management A/S with affiliates Carmo A/S, Bolux A/S with affiliates and Labflex A/S. Member of NASDAQ OMX Copenhagen advisory board.
Marianne Weile has since 2009 been elected for the board of BioPorto. Since 2000, Marianne Weile has been with Novozymes and is Director for Patents & Licensing. Previously, Marianne Weile was a consultant with Dansk Industri and with Copenhagen Science Park Symbion and over a number of years she has focused on innovation, technology and start-up of companies, including the start-up of her own company. Marianne Weile has solid experience within IPR, licensing and business development combined with insight into the biotech industry and experience with smaller companies.
Marianne Weile is born in 1960 and has a bachelor in Biochemistry fra Copenhagen University (1986) ans an MBA from Copenhagen Business School (1997).
Directorships: Member of the board of BioPorto A/S
Roar Bjørk Seeger has since 2011 been the Director of Lion & Dolphin A/S and Vidis GmbH with the overall responsibility for brand building and building distributor networks. Previously, he was Director of Modstrøm A/S, building the first climate friendly power retailer. Roar Bjørk Seeger also has several years of experience in the telecommunications industry within sales and marketing.
Roar Bjørk Seeger was born in 1964 and holds an MBA in Technology, Market and Organisation from Copenhagen Business School (2005) and a military education.
Directorships: Chairman of the board in Modstrøm Danmark A/S. Board member in Aktant Technology Denmark A/S, Aktant Technology and BRS Holding Int. ApS. Director of Lion & Dolphin A/S, BRS Holding Int. ApS and Seeger.
Thomas Magnussen is Chairman and co-founder and partner in QuantumWise A/S and Zylinc A/S respectively as well as an entrepreneur in the high-tech space, start-up companies with global business scope. Thomas Magnussen has experience in commercialization strategies and from industries including nanotechonolgy, ICT and medtech.
Thomas Magnussen holds an MBA from INSEAD and a Ph.D. and M.S. from DTU.
Directorships: Chairman of the board in QuantumWise A/S and Zylinc A/S, Director of Therazone ApS.
Laura von Kobyletzki heads the County Councils Department of Research, Development and Education, Primary Care, Karlstad as well as research leader. Laura von Kobyletzki has led several international research projects and cooperates with several European universities and have experience with validation of diagnostic criteria for determining disease severity.
Laura von Kobyletzki was born in 1971 and is a specialist in general medicine and M.Sc. in epidimology from the London School of Hygiene and Tropical Medicine and is currently finishing a PhD in Medicine at the Department of Clinical Research, Lund University.
Torben A. Nielsen has over the past 25 years held senior positions in the financial sector – the last 10 years as member of the executive management in Sydbank responsible for asset management, capital markets, treasury, foreign and several other business areas as well as CEO of BankInvest. Concurrently, he has held several national and international board memberships, including NASDAQ OMX. Of a total of 30 years in the financial sector, of which 5 years in New York and London, Torben A. Nielsen built and managed businesses at home and abroad in all relevant commercial business areas in the financial sector and has been involved in and responsible for several mergers and acquisitions.
Torben A. Nielsen was born in 1960 and holds DIEUs top management education VL (2006) and a banking education.
Claus Crone Fuglsang has since 1993 been with Novo Nordisk and Novozymes, where he is currently VP of BioEnergy R&D globally. Claus Crone Fuglsang has worked as a researcher, then as Head of Department and Director of Novozymes Protein Chemistry and Pharmaceutical research. He has extensive experience in managing large research organizations and strategic management of reseach and driving innovation into product development. He also has extensive experience in negotiating reseach and business agreements at an international level and is part of several cross-organizational management teams for these agreements with representation from the participating companies.
Claus Crone Fuglsang was born in 1968 and holds a M.Sc. in Biochemistry from the University of Copenhagen (1993) and an MBA from Heriot-Watt University, Edinburgh (2000).
Carsten Lønfeldt, Chairman of the Board of Directors
Christina Thomsen, Investor Relations
Tel. no. (+45) 45 29 00 00, e-mail firstname.lastname@example.org